UCB Announces U.S. FDA Approval of RYSTIGGO[®] (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis What you need to know: This is a new therapy that is designed as a monoclonal antibody that binds to the neonatal Fc receptor (FcRN). The delivery of this therapy is subcutaneous injection – so it’s quicker and… Read more »
Posts Categorized: featured
COVID and Myasthenia
COVID continues to be a concern if you are immunocompromised or have a weakened immune system because of a medical condition or a treatment for a condition. This is the case if you have myasthenia gravis, and are taking immuno-suppressant medication. The Centers for Disease Control continues to recommenf that those who are immunocompromised or… Read more »
MG Activities of Daily Living (MG-ADL) Scale
With a disease like myasthenia that fluctuates from day to day and even more from month to month, it can be challenging to get a clear picture of a person’s illness. Your doctor can assess your myasthenia with several different tracking tools. One of these measures is called the MG Activities of Daily Living scale,… Read more »
Patient Experience with Pyridostigmine
In January 2022, an Illinois-based specialty pharmaceutical company collaborated on a project with Conquer MG to gain insights from MG patients. Conquer MG helped with study review and recruitment, and a study of 102 MG patients was conducted that addressed their use of pyridostigmine (brand name Mestinon®). Pyridostigmine is typically the first drug MG patients… Read more »
10th Annual Viking Challenge Recap
Viking Challenge for MG 2022 Walkers, volunteers, and sponsor reps – 110 in all – gathered on June 19, 2022, in Elmhurst, Illinois, to kick off the 10th Annual Viking Challenge for Myasthenia Gravis. It was the first in-person event for this group in two years, and each person was prepared to rally in support… Read more »
